Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CCR1 | P32246 | 2/20 | 0.47 |
| ▸ | CCR5 | P51681 | 2/20 | 0.47 |
| ▸ | CCR8 | P51685 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.38 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31419299 | 0.87 | CYP1A2 (0.43) | CYP1A2CCR1CCR5CCR8ALDH1A1 | |
| SCHEMBL5509853 | 0.84 | ALDH1A1 (0.50) | CYP1A2CCR1CCR5CCR8ALDH1A1 | |
| SCHEMBL4540744 | 0.84 | CYP1A2 (0.57) | CYP1A2CCR1CCR5CCR8ALDH1A1 | |
| SCHEMBL29612573 | 0.84 | CYP1A2 (0.57) | CYP1A2CCR1CCR5CCR8ALDH1A1 | |
| SCHEMBL4572536 | 0.83 | CYP1A2 (0.65) | CYP1A2CCR1CCR5CCR8ALDH1A1 | |
| SCHEMBL20528292 | 0.83 | BACE1 (0.47) | CYP1A2ALDH1A1BACE1MALT1BIRC5 | |
| SCHEMBL18856407 | 0.77 | MAOB (0.38) | CYP1A2ALDH1A1PSMB5TNFKDM4E | |
| SCHEMBL21632275 | 0.76 | CYP1A2 (0.57) | CYP1A2CCR1CCR5CCR8ALDH1A1 | |
| SCHEMBL22520176 | 0.76 | CYP1A2 (0.57) | CYP1A2CCR1CCR5CCR8ALDH1A1 | |
| SCHEMBL5537413 | 0.76 | CYP1A2 (0.57) | CYP1A2CCR1CCR5CCR8ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528791-B2 | Thyroid hormone receptor beta agonist compounds | TERNS PHARMACEUTICALS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4547658-A1 | WEE1 DEGRADING COMPOUNDS AND USES THEREOF | Bristol-Myers Squibb Company (US) | 2025-05-07 | — | — | EP | disclosed |
| EP-4055014-B1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | YUHAN CORP (KR) | 2025-04-30 | — | — | EP | disclosed |
| CN-119325469-A | WEE1 degrading compounds and uses thereof | 百时美施贵宝公司 | 2025-01-17 | — | — | CN | disclosed |
| CN-114867719-B | Pyrrolidine and piperidine compounds | 柳韩洋行 | 2024-06-25 | — | — | CN | disclosed |
| WO-2024059186-A1 | N-((ISOQUINOLIN-6-YL)METHYL)-1H-PYRAZOLE-4-CARBOXAMID DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS FOR THE TREATMENT OF HEREDITARY ANGIOEDEMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-03-21 | — | — | WO | disclosed |
| US-20240067632-A1 | WEE1 Degrading Compounds and Uses Thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-29 | — | — | US | disclosed |
| WO-2024006881-A1 | WEE1 DEGRADING COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-04 | — | — | WO | disclosed |
| US-11655235-B2 | Pyrrolidine and piperidine compounds | YUHAN CORPORATION (KR) | 2023-05-23 | — | — | US | disclosed |
| EP-4055014-A1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | Yuhan Corporation (KR) | 2022-09-14 | — | — | EP | disclosed |
| US-9745329-B1 | Method of preparing silylative-reduced N-heterocyclic compound using organoboron catalyst | INSTITUTE FOR BASIC SCIENCE (KR) | 2017-08-29 | — | — | US | disclosed |
| US-20170240572-A1 | METHOD OF PREPARING SILYLATIVE-REDUCED N-HETEROCYCLIC COMPOUND USING ORGANOBORON CATALYST | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2017-08-24 | — | — | US | disclosed |
| WO-2016076479-A1 | METHOD OF PREPARING SILYLATIVE-REDUCED N-HETEROCYCLIC COMPOUND USING ORGANOBORON CATALYST | INSTITUTE FOR BASIC SCIENCE (KR) | 2016-05-19 | — | — | WO | disclosed |
| US-20080214455-A1 | Novel Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-09-04 | — | — | US | disclosed |
| US-20050227978-A1 | Fibrosis inhibitor | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2005-10-13 | — | — | US | disclosed |
| EP-1479384-A1 | FIBROSIS INHIBITOR | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-11-24 | — | — | EP | disclosed |
| US-20040209939-A1 | Pyrrole derivatives | SUMITOMO PHARMACEUTICALS CO., LTD. | 2004-10-21 | — | — | US | disclosed |
| US-6759429-B2 | HAVING TRANSFORMING GROWTH FACTOR- BETA INHIBITORY ACTIVITY AND BEING USEFUL AS FIBROSIS INHIBITORS FOR ORGANS OR TISSUES | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2004-07-06 | — | — | US | disclosed |
| US-20030181496-A1 | Pyrrole derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2003-09-25 | — | — | US | disclosed |
| EP-1310485-A1 | PYRROLE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227978-A1 | Fibrosis inhibitor | SMAD3, MMP1, SMAD2 | CYP1A2 654/4885CCR1 23/4885CCR5 228/4885 |
| US-20170240572-A1 | METHOD OF PREPARING SILYLATIVE-REDUCED N-HETEROCYCLIC COMPOUND USING ORGANOBORON CATALYST | NISCH, SRI, SEPTIN8 | CYP1A2 777/4885CCR1 2611/4885CCR5 1961/4885 |
| US-12528791-B2 | Thyroid hormone receptor beta agonist compounds | THRB, THRA, TSHR | CYP1A2 1493/4885CCR1 382/4885CCR5 534/4885 |
| US-20030181496-A1 | Pyrrole derivatives | NCOA1, PKD1, NR3C2 | CYP1A2 273/4885CCR1 15/4885CCR5 237/4885 |
| US-11655235-B2 | Pyrrolidine and piperidine compounds | FAP, APC, VHL | CYP1A2 1528/4885CCR1 1821/4885CCR5 2251/4885 |
| US-20080214455-A1 | Novel Chemical Compounds | HIPK3, HIPK1, HIPK4 | CYP1A2 4720/4885CCR1 4635/4885CCR5 4496/4885 |
| US-20240067632-A1 | WEE1 Degrading Compounds and Uses Thereof | WEE1, WEE2, PPME1 | CYP1A2 3456/4885CCR1 4181/4885CCR5 4526/4885 |
| US-20040209939-A1 | Pyrrole derivatives | NCOA1, PKD1, NCOR1 | CYP1A2 250/4885CCR1 14/4885CCR5 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.